Market Cap 830.72M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 985,900
Avg Vol 1,461,764
Day's Range N/A - N/A
Shares Out 138.92M
Stochastic %K 66%
Beta 1.27
Analysts Strong Sell
Price Target $17.22

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
VIR_Tical1
VIR_Tical1 Oct. 27 at 7:26 PM
$VIR Update: https://tipranks.onelink.me/WJho/lylvv6on
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 5:53 PM
$VIR Arch Venture Fund IX, L.P.: This is a 10% owner and holds about 28,666,663 shares. Arch Venture Partners, L.P.: Holds approximately 12,916,663 shares, or about 9.30% of the company. ARCH Venture Partners IX LP: Holds 5,626,008 shares, or about 4.05%. Arch Venture Fund IX Overage, L.P.: Holds 7,290,655 shares, or about 5.25%.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 5:45 PM
$VIR how come Arch Ventures purchase about 15-20% of Vir’s shares without informing the Nasdaq, they could only have purchased them from a institutional holder or direct from Vir. I don’t know of any institution with such a large stake, Vir got consent to issue more shares via a ’mixed shelf offering’ so they could have purchased them direct & although this would cause some dilution it would be offset by Vir banking $65M. My point is why hasn’t the purchase be announced via the stock exchange, any stake over i think 3% requires notification. Arch could own over 20% now.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:36 AM
$VIR Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners ... Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), ...
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:35 AM
$VIR my previous posts taken from marketbeat are the most exciting i’ve read about Vir in a long time. Robert Nelson set up Arch Ventures Management Ltd to invest in start up biotech co’s & if they have invested a ’further’ $65,100,000 then there must be positive news coming.
0 · Reply
big_dipper1546
big_dipper1546 Oct. 26 at 1:23 AM
$VIR rate cut is supposed to be bullish for biotech. Could be normal capital deployment and allocation. Nothing to do with fundamentals.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:18 AM
$VIR Sato serves both Vir & Arch & is in fact a ’venture partner’ at Arch who have invested $65,100,000 in Vir. Vicki Sato, Ph.D., has served as Chairman of our Board since December 2016. Dr. Sato is currently a venture partner at ARCH Venture Partners, Chairman of the Board at Denali Therapeutics, a member of the board of directors of Allogene Therapeutics, Inc. and a member of the National Academies of Sciences, Engineering and Medicines’ Committee on Science, Technology and Law. In addition, she served on President Biden’s Council of Advisors in Science and Technology (PCAST) from 2021 to 2025.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:09 AM
$VIR with regard to my previous postings, Arch Ventures are the founder investors in Vir we have directors who serve on both companies boards, Vicki Sato our chairman for one, Sato also has major stakes in Arch & Vir. Something big is coming if Arch have invested a further $65,000,000 in Vir.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:01 AM
$VIR https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-major-shareholder-endurance-cayman-ltd-svf-sells-154383-shares-2025-10-24/
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 12:16 AM
$VIR A-numbe of institutional investors have recently modified their holdings of the company. ARCH Venture Management LLC bought a new stake in Vir Biotechnology during the second quarter worth about $65,100,000. Orbimed Advisors LLC raised its holdings in Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company's stock worth $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vir Biotechnology by 9.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock worth $8.X,909,000 after acquiring an additional 122,219 shares in the last quarter. Aberdeen Group plc raised its holdings in Vir Biotechnology by 45.3% during the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company's stock worth $5,075,000 after acquiring an additional 313,699 shares in the last quart
1 · Reply
Latest News on VIR
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:01 PM EDT - 2 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript


Vir Biotechnology: Hep B And Cancer Projects March On

Jul 23, 2025, 12:10 PM EDT - 3 months ago

Vir Biotechnology: Hep B And Cancer Projects March On


Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 6 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript


Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 8 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript


Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 10 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data


Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:12 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript


VIR_Tical1
VIR_Tical1 Oct. 27 at 7:26 PM
$VIR Update: https://tipranks.onelink.me/WJho/lylvv6on
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 5:53 PM
$VIR Arch Venture Fund IX, L.P.: This is a 10% owner and holds about 28,666,663 shares. Arch Venture Partners, L.P.: Holds approximately 12,916,663 shares, or about 9.30% of the company. ARCH Venture Partners IX LP: Holds 5,626,008 shares, or about 4.05%. Arch Venture Fund IX Overage, L.P.: Holds 7,290,655 shares, or about 5.25%.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 5:45 PM
$VIR how come Arch Ventures purchase about 15-20% of Vir’s shares without informing the Nasdaq, they could only have purchased them from a institutional holder or direct from Vir. I don’t know of any institution with such a large stake, Vir got consent to issue more shares via a ’mixed shelf offering’ so they could have purchased them direct & although this would cause some dilution it would be offset by Vir banking $65M. My point is why hasn’t the purchase be announced via the stock exchange, any stake over i think 3% requires notification. Arch could own over 20% now.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:36 AM
$VIR Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners ... Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), ...
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:35 AM
$VIR my previous posts taken from marketbeat are the most exciting i’ve read about Vir in a long time. Robert Nelson set up Arch Ventures Management Ltd to invest in start up biotech co’s & if they have invested a ’further’ $65,100,000 then there must be positive news coming.
0 · Reply
big_dipper1546
big_dipper1546 Oct. 26 at 1:23 AM
$VIR rate cut is supposed to be bullish for biotech. Could be normal capital deployment and allocation. Nothing to do with fundamentals.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:18 AM
$VIR Sato serves both Vir & Arch & is in fact a ’venture partner’ at Arch who have invested $65,100,000 in Vir. Vicki Sato, Ph.D., has served as Chairman of our Board since December 2016. Dr. Sato is currently a venture partner at ARCH Venture Partners, Chairman of the Board at Denali Therapeutics, a member of the board of directors of Allogene Therapeutics, Inc. and a member of the National Academies of Sciences, Engineering and Medicines’ Committee on Science, Technology and Law. In addition, she served on President Biden’s Council of Advisors in Science and Technology (PCAST) from 2021 to 2025.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:09 AM
$VIR with regard to my previous postings, Arch Ventures are the founder investors in Vir we have directors who serve on both companies boards, Vicki Sato our chairman for one, Sato also has major stakes in Arch & Vir. Something big is coming if Arch have invested a further $65,000,000 in Vir.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 1:01 AM
$VIR https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-major-shareholder-endurance-cayman-ltd-svf-sells-154383-shares-2025-10-24/
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 26 at 12:16 AM
$VIR A-numbe of institutional investors have recently modified their holdings of the company. ARCH Venture Management LLC bought a new stake in Vir Biotechnology during the second quarter worth about $65,100,000. Orbimed Advisors LLC raised its holdings in Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company's stock worth $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vir Biotechnology by 9.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock worth $8.X,909,000 after acquiring an additional 122,219 shares in the last quarter. Aberdeen Group plc raised its holdings in Vir Biotechnology by 45.3% during the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company's stock worth $5,075,000 after acquiring an additional 313,699 shares in the last quart
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 24 at 8:52 PM
$VIR Softbank offloaded another 298,549 shares, they’re shifting quite a lot of shares at the moment but still have 14,711,635 left. Slightly concerning but someone’s buying them.
0 · Reply
nUme22
nUme22 Oct. 23 at 7:18 PM
$VIR feels like this is going below 5 soon
0 · Reply
Mhand
Mhand Oct. 23 at 6:08 PM
$VIR WTF is up this afternoon? Softbank at it again? Who's buying?
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 22 at 10:06 PM
$VIR Softbank have reported further sales of aprox 220,000 & 109,000 leaving them with just over 15m shares.
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 22 at 1:07 PM
$VIR Softbank disposed of 834,000 shares, only another 138m shares left. Could be for a variety of reasons but market makers will only take on what they can sell on, they are not stock holders.
1 · Reply
Njdude
Njdude Oct. 20 at 10:21 PM
$VIR 49 cents on no news ??
0 · Reply
Njdude
Njdude Oct. 18 at 11:19 PM
$VIR https://abcnews.go.com/amp/Health/wireStory/fda-unveils-drugs-receive-expedited-review-support-national-126598808
0 · Reply
Njdude
Njdude Oct. 18 at 11:18 PM
$VIR FDA just released 9 drugs that are experimental and VIR was not one of them and 1 was for Hepatitis. Sadness
0 · Reply
Floridahrrcn
Floridahrrcn Oct. 17 at 2:03 PM
$VIR long term holder but what’s up with all insiders selling all the time?
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Oct. 16 at 7:15 PM
$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS
2 · Reply
Dunnieboy1
Dunnieboy1 Oct. 15 at 6:35 PM
$VIR released 3hours ago;In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $15.00. The company’s shares opened today at $5.73
1 · Reply
Dunnieboy1
Dunnieboy1 Oct. 15 at 8:57 AM
$VIR Softbank have disposed of around 250,000 shares still leaving them with well over 15m shares.
1 · Reply